Database of patients with pancreatic neoplasms
Official title: Institut Paoli-Calmettes Pancreatic Neoplasms Database
Run by Institut Paoli-Calmettes · NCT02869581 · Data updated 2026-11-12
This study is creating a database to collect information from patients with pancreatic tumors to help researchers understand their condition better and improve future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 8500 (estimated) |
| Sponsor | Institut Paoli-Calmettes Academic / other |
| Locations | 1 site (Marseille, Bouches du Rhone) |
| Status | Recruiting |
| Started | January 2000 |
| Main results expected | January 2030 |
| Study ends | December 2030 |
| Registry record updated | August 17, 2016 |
| Trial ID | NCT02869581 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with pancreatic neoplasms.
✕Probably not a fit
Patients diagnosed with cholangiocarcinoma will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study involves the creation of a comprehensive database at the Institut Paoli-Calmettes for patients diagnosed with pancreatic neoplasms. The primary focus is on collecting and organizing clinical data to better understand the characteristics and outcomes of these patients. By gathering this information, researchers aim to facilitate future studies and improve treatment strategies for pancreatic neoplasms. The observational nature of the study means that it will not involve any experimental interventions but will rely on existing patient data.
Why it matters
Potential benefit: If successful, this database could enhance understanding of pancreatic neoplasms and lead to improved patient management and treatment options.
How similar studies have gone: While this approach of creating a patient database is common, the specific focus on pancreatic neoplasms may provide novel insights that have not been extensively explored in previous studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with a diagnosis of Pancreatic neoplasm Exclusion Criteria: * Patient with a diagnosis of cholangiocarcinoma
Where it's running
-
Institut Paoli Calmettes
Marseille, Bouches du Rhone, France Recruiting
Study contacts
- Study coordinator: Dominique Genre, MD
- Email: drci.up@ipc.unicancer.fr
- Phone: 0033491223778
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Energy needs after pancreatic surgery: measuring metabolism to guide nutrition
This study tests how much energy patients need after pancreatic surgery and compares direct measurements with common estimating methods to see if standard formulas are accurate.
-
Liquid biopsy biomarkers to detect and monitor pancreatic cancer
Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.
-
Indocyanine green–guided laparoscopic distal pancreatectomy vs standard approach for pancreatic body/tail lesions
This trial tests whether using indocyanine green (ICG) fluorescence during laparoscopic distal pancreatectomy helps surgeons protect blood flow and structures, compared with the standard approach, in adults with pancreatic body or tail tumors.
-
Pancreatic Surgery and New Diabetes Risk in Adults without Diabetes
This study tests whether removing part or all of the pancreas during surgery affects blood sugar control and metabolism in adults who did not have diabetes before the operation.
-
Pancreatic Cancer Screen Test in Japan Using the Enzeavour Blood Assay
This nationwide screening study in Japan tests the Enzeavour Pancreatic Cancer blood test in about 10,000 asymptomatic adults to see if it can help detect pancreatic cancer early.
-
NEO-Match nanomechanical testing of pancreatic tumor samples
This will test whether the NEO-Match® nanomechanical test on biopsy tissue can help predict response to pre-surgery treatment and detect cancer in people with suspected pancreatic tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.